Research published in Nature Communications co-led by Monash Biomedicine Discovery Institute (BDI)’s Professor Max Cryle and colleagues from the University of Tübingen has, for the first time, characterised and tested the evolution of glycopeptide antibiotics (GPAs) both computationally and experimentally. By altering the strain that produces these compounds, they have biosynthesised the ancestral GPA paleomycin. The design principles can be used to change these antibiotics to make new compounds to fight antimicrobial resistance.

Read the Monash BDI story
[ Ссылка ]

Nature Communications article:
[ Ссылка ]

Learn more about Monash BDI
Website: [ Ссылка ]
X (Formerly known as Twitter): [ Ссылка ]
Facebook: [ Ссылка ]

свернуть